$2.38 Million in Sales Expected for Curis, Inc. (NASDAQ:CRIS) This Quarter

Equities analysts forecast that Curis, Inc. (NASDAQ:CRISGet Rating) will report $2.38 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Curis’ earnings, with the highest sales estimate coming in at $2.41 million and the lowest estimate coming in at $2.35 million. Curis posted sales of $2.29 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3.9%. The company is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Curis will report full-year sales of $10.65 million for the current year, with estimates ranging from $10.60 million to $10.74 million. For the next fiscal year, analysts anticipate that the company will report sales of $10.76 million, with estimates ranging from $10.62 million to $10.88 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Curis.

Curis (NASDAQ:CRISGet Rating) last released its earnings results on Thursday, May 5th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $2.21 million. Curis had a negative return on equity of 54.04% and a negative net margin of 490.80%. During the same period in the previous year, the firm earned ($0.11) earnings per share.

Several equities research analysts have recently issued reports on the company. Raymond James lowered Curis from an “outperform” rating to a “market perform” rating and set a $15.00 price target for the company. in a report on Monday, April 4th. Zacks Investment Research downgraded Curis from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. StockNews.com upgraded Curis from a “sell” rating to a “hold” rating in a research report on Thursday, May 12th. B. Riley lowered their price target on Curis from $22.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th. Finally, Cantor Fitzgerald reduced their price objective on Curis from $12.00 to $4.00 in a research note on Tuesday, April 5th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Curis currently has a consensus rating of “Buy” and a consensus target price of $10.85.

A number of hedge funds have recently modified their holdings of CRIS. Engineers Gate Manager LP bought a new stake in shares of Curis in the 1st quarter valued at $32,000. Cutler Group LP increased its position in Curis by 46.3% in the fourth quarter. Cutler Group LP now owns 9,800 shares of the biotechnology company’s stock worth $46,000 after buying an additional 3,100 shares during the last quarter. Virtu Financial LLC purchased a new stake in Curis in the fourth quarter worth $49,000. Advisor Group Holdings Inc. increased its position in Curis by 36.1% in the third quarter. Advisor Group Holdings Inc. now owns 7,540 shares of the biotechnology company’s stock worth $58,000 after buying an additional 2,000 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Curis by 198.5% during the second quarter. Royal Bank of Canada now owns 8,357 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 5,557 shares during the period. Institutional investors and hedge funds own 78.15% of the company’s stock.

Shares of CRIS opened at $0.87 on Tuesday. Curis has a 1-year low of $0.70 and a 1-year high of $15.60. The business’s 50-day moving average price is $1.14 and its 200 day moving average price is $2.83.

About Curis (Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Featured Stories

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.